Influence of IL28B polymorphisms on response to a lower-than-standard dose peg-IFN-α 2a for genotype 3 chronic hepatitis C in HIV-coinfected patients

• Published in: PloS one Vol. 7; no. 1; p. e28115
• Main Authors: López-Cortés, Luis F, Ruiz-Valderas, Rosa, Jimenez-Jimenez, Luis, González-Escribano, María F, Torres-Cornejo, Almudena, Mata, Rosario, Rivero, Antonio, Pineda, Juan A, Marquez-Solero, Manuel, Viciana, Pompeyo
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 2012; Public Library of Science (PLoS)
• Subjects: Adult; Biology; Biopsy; Dose-Response Relationship, Drug; Female; Genotype; Genotype & phenotype; Genotypes; Hepatitis; Hepatitis C; Hepatitis C, Chronic - complications; Hepatitis C, Chronic - drug therapy; Hepatitis C, Chronic - genetics; Hepatitis C, Chronic - metabolism; Hepatology; HIV; HIV Infections - complications; Human immunodeficiency virus; Humans; Infections; Interferon; Interferon-alpha - adverse effects; Interferon-alpha - pharmacokinetics; Interferon-alpha - therapeutic use; Interferons; Interleukins - genetics; Liver; Male; Medicine; Middle Aged; Motivation; Patients; Polyethylene glycol; Polyethylene Glycols - adverse effects; Polyethylene Glycols - pharmacokinetics; Polyethylene Glycols - therapeutic use; Polymorphism, Single Nucleotide; Recombinant Proteins - adverse effects; Recombinant Proteins - pharmacokinetics; Recombinant Proteins - therapeutic use; Ribavirin; Ribavirin - pharmacokinetics; Ribavirin - therapeutic use; Ribonucleic acid; RNA; Safety; Therapy; Treatment Outcome; Viremia; α-Interferon; Spain

Data on which to base definitive recommendations on the doses and duration of therapy for genotype 3 HCV/HIV-coinfected patients are scarce. We evaluated the efficacy of a lower peginterferon-α 2a dose and a shorter duration of therapy than the current standard of care in genotype 3 HCV/HIV-coinfect...